Accuracy of Airflow Obstruction Thresholds for Predicting COPD-Related Hospitalization and Mortality Can Simple Diagnostic Thresholds Be Used for a Complex Disease? by Vestbo, Jørgen & Lange, Peter
u n i ve r s i t y  o f  co pe n h ag e n  
Accuracy of Airflow Obstruction Thresholds for Predicting COPD-Related
Hospitalization and Mortality Can Simple Diagnostic Thresholds Be Used for a
Complex Disease?
Vestbo, Jørgen; Lange, Peter
Published in:







Citation for published version (APA):
Vestbo, J., & Lange, P. (2019). Accuracy of Airflow Obstruction Thresholds for Predicting COPD-Related
Hospitalization and Mortality Can Simple Diagnostic Thresholds Be Used for a Complex Disease? J A M A: The
Journal of the American Medical Association, 321(24), 2412-2413. https://doi.org/10.1001/jama.2019.6584




Accuracy of Airflow Obstruction Thresholds for Predicting COPD-related 
Hospitalization and Mortality: 
  Can simple diagnostic thresholds be used for a complex disease?  
 
 




1. Division of Infection, Immunity and Respiratory Medicine, University of Manchester, 
Manchester Academic Health Science Centre, Manchester, UK 
 
2. North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK 
 
3. Institute of Public Health, Section of Epidemiology, Copenhagen University, Denmark 
 
4. Medical Department, Respiratory Section, Herlev-Gentofte Hospital, Copenhagen 
University, Herlev, Denmark. 
 
 
Correspondence: Professor Jørgen Vestbo 
  2nd Floor, ERC Building 
  Wythenshawe Hospital 
  Southmoor Road 
  M23 9LT Manchester 
  UK 
 
  Phone: +45 30350317 
  Mail: jorgen.vestbo@manchester.ac.uk 
 
 




Diagnostic criteria for complex chronic diseases often include a threshold for a biomarker. In 
the case of chronic obstructive pulmonary disease (COPD) and hypertension, physiological 
biomarkers are applied. For COPD, the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) states that in a symptomatic individual with a relevant exposure (such as smoking), “the 
presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow 
limitation and thus of COPD” (1). A decreased ratio between forced expiratory volume in 1 second 
(FEV1) and forced vital capacity (FVC) is an accepted measure of airflow limitation, but debate 
around the most accurate threshold level has been ongoing for decades (2,3).  
In this issue of JAMA, Bhatt et al. (4) showed that the simple fixed ratio of FEV1/FVC < 0.7 for 
defining airflow obstruction has the same prognostic value regarding COPD-related hospital 
admissions and mortality as using the lower limit of normal (LLN, defined as the lower 2.5th 
percentile of a healthy reference group adjusted for age, sex, race, and height) of the ratio as 
threshold. The authors used pooled data from 24,103 adults (mean age at baseline, 63 years) from 
four well-characterized US cohorts [Atherosclerosis Risk in Communities Study (ARIC), 
Cardiovascular Health Study (CHS), Health, Aging and Body Composition Study (HealthABC) and 
Multi-Ethnic Study of Atherosclerosis (MESA)] to determine the discriminative accuracy of various 
FEV1/FVC fixed thresholds for predicting COPD-related events (ie, hospitalization and mortality). 
The presence of airflow obstruction was defined by FEV1/FVC less than a range of fixed thresholds 
(0.75 to 0.65) or the lower-limit-of-normal (LLN), defined by Global Lung Initiative (GLI) reference 
equations. The optimal fixed FEV1/FVC threshold, defined by the best discrimination of COPD-
related events, was evaluated based on 3793 COPD-related events that occurred over a median 
follow-up of 15 years. Compared to a covariates-only model (c statistic, 0.680), the FEV1/FVC<0.70 
threshold optimized discrimination of COPD-related events (c statistic, 0.760, incremental c 
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statistic for improved discrimination, 0.079, P<0.0001) and had discrimination that was not 
significantly different compared with the LLN (c statistic, 0.762, P=0.55 versus c-statistic for 
FEV1/FVC <0.70). Compared with the LLN, the fixed threshold of 0.70 demonstrated lower 
specificity (79% vs 88%), and higher sensitivity (65% vs 50%). 
These findings invariably raise the question – why use a spirometry threshold for diagnosing 
COPD?  Breathlessness is frequent in middle-aged and elderly smokers and can have numerous 
causes. Detecting the presence of airflow limitation makes it likely that the patient’s symptoms 
can be ascribed to lung disease, and a number of studies have documented that even mild fixed 
airflow limitation can lead to physiological impairment (5). However, as multimorbidity is the rule 
rather than an exception in patients with COPD, excluding other causes of breathlessness, in 
particular heart disease, is mandatory (6). 
Most clinicians will agree that many patients with COPD are diagnosed too late because 
spirometry is not routinely performed in symptomatic smokers. It is also clear that with increasing 
awareness of COPD many symptomatic smokers are labelled as having COPD until eventually a 
spirometric examination shows the absence of airflow limitation. The limited uptake of spirometry 
outside the field of respiratory medicine poses a much larger problem than the definition of the 
exact threshold debated among respiratory specialists. In addition to mis- and under-diagnosis 
because of the lack of spirometry, misdiagnosis among individuals with airflow limitation 
documented with spirometry should also be mentioned. For many years, misclassification 
between COPD and asthma would most often imply that many individuals with COPD were 
misclassified as having asthma. However, with increasing awareness of COPD, there is now a need 
to emphasize that not all individuals with airflow limitation have COPD and that, instead, a 
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substantial number of them have late-onset asthma with important implications regarding the 
choice of medical treatment.  
The use of either a fixed threshold (which is not adjusted for age, sex, race, ore height) or 
LLN (which is adjusted) has advantages and disadvantages. A fixed threshold will invariably be 
biased by age. Undoubtedly, LLN for the FEV1/FVC ratio is a better measure of airflow limitation in 
general because LLN adjusts for the strong association between increasing age and decreasing 
FEV1/FVC ratio in healthy individuals. However, for use as a diagnostic criterion in a symptomatic 
individual with an exposure history relevant to COPD (most often smoking), this advantage of LLN 
may not be that important.  Other potential limitations to using the FEV1/FVC criterion could be 
more important. First, COPD is mainly a disease of the small airways and the lung parenchyma, 
whereas the FEV1 is primarily a measure of airflow in central airways. For this reason, the 
FEV1/FVC ratio, particularly using a fixed ratio, is an insensitive measure of early disease. In 
addition, FEV1/FVC may be only minimally affected in persons with early emphysema, mild 
emphysema, or both, an important component of COPD and often associated with progressive 
disease (7,8). Also, with increasing rates of obesity, the influence of body mass index (BMI) on 
FEV1/FVC should not be underestimated. Since FEV1/FVC increases with increasing levels of BMI, 
COPD may be underdiagnosed when the usual criteria are applied in the obese individuals (9). 
Bhatt et al. used data from large US epidemiological studies, and consequently based their 
analyses on pre-bronchodilator spirometry obtained at study baseline. This approach is common 
in epidemiological settings but differs from diagnostic criteria as stated in guidelines, in which 
spirometry following the administration of an inhaled bronchodilator is advocated. This distinction 
has always caused a dilemma, because virtually all current knowledge of the natural history of 
COPD has been derived from studies with repeated pre-bronchodilator measurements. It is 
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uncertain whether the use of pre- rather than post-bronchodilator spirometry may have affected 
the prognostic value of the cut-points examined by Bhatt et al. However, a Norwegian population 
study that included use of a bronchodilator indicated that airflow limitation may be over-
diagnosed by up to 25% when a pre-bronchodilator, rather than a post-bronchodilator, FEV1/FVC 
ratio is used (10).  On the other hand, a pragmatic study from the Netherlands comparing different 
spirometric indices performed in a setting of general practice, reported that a fixed FEV1/FVC 
actually performed better than LLN in diagnosing COPD and that there was no difference in 
diagnostic accuracy when using either pre- or post-bronchodilator FEV1/FVC (11).  There is also 
uncertainty associated with using only a single FEV1/FVC measurement for making a diagnosis; as 
an analogy, it would be unlikely that a clinician would diagnose hypertension based on a single 
measurement of elevated blood pressure. The FEV1/FVC can vary substantially around the 
threshold value of 0.7 (12), and repeated measurements are therefore recommended (1). 
Moreover, in an age of precision medicine and hope of pathway-driven treatments, it does 
not make sense to diagnose a disease based on a simple physiological measurement.   Like most 
other common chronic diseases, COPD is heterogeneous with several different components and 
likely many different pathways leading to the disease, as illustrated by the different trajectories of 
FEV1 leading to COPD (13). In addition, although a better understanding is emerging of the 
genetics of COPD (14) and the interactions of small airways disease and emphysema, further 
research is needed to define subsets of COPD based on mechanisms. While waiting, clinicians may 
be best advised to continue to use an old, simple measurement for this complex disorder. Now, 
based on the findings reported in the study of Bhatt and colleagues (4), this simple measurement 
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